{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:00:36Z","timestamp":1788199236341,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100021828","name":"German Academic Exchange Service","doi-asserted-by":"publisher","award":["57657089"],"award-info":[{"award-number":["57657089"]}],"id":[{"id":"10.13039\/100021828","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universitas Indonesia, PUTI Q1","award":["NKB-395\/UN2.RST\/HKP.05.00\/2024"],"award-info":[{"award-number":["NKB-395\/UN2.RST\/HKP.05.00\/2024"]}]},{"DOI":"10.13039\/501100008977","name":"Universit\u00e4t Ulm","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008977","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Phys"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>The aim of this study was to investigate the accuracy and precision of single-time-point (STP) dosimetry using a physiologically-based pharmacokinetic (PBPK) model with non-linear mixed-effects modelling (NLMEM).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Biokinetic data of [<jats:sup>111<\/jats:sup>In]In-DOTA-TATE in tumours, kidneys, liver, spleen, and whole body were collected from eight patients. The imaging was performed using planar scintigraphy at 2, 4, 24, 48, and 72\u00a0h after injection. Serum activity concentration was quantified at 5 and 15\u00a0min; 0.5, 1, 2, and 4\u00a0h; and 1, 2, and 3 d after injection. The PBPK model was fitted to the biokinetic data using NONMEM software version 7.5.1. Goodness-of-fit (GoF) criteria were visual inspection of the biokinetic curves, relative standard errors (RSEs) of the fitted parameters\u2009&lt;\u200950%, and the absolute values of the off-diagonal elements in the correlation matrix\u2009&lt;\u20090.8. All-time-point (ATP) fitting was performed, and the obtained absorbed doses (ADs) were used as reference (rADs). The leave-one-out Jackknife method was applied to calculate STP ADs (sADs). The accuracy of STP dosimetry was evaluated using the relative deviation between sADs and rADs. The time point, which resulted in the smallest root-mean-square error (RMSE), was selected as the optimal time point for STP dosimetry. The precision of the AD was calculated as ratio of AD RSE and AD values.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The ATP fitting was adequate based on the GoF test. STP dosimetry\u00a0at 48\u00a0h after injection provided an acceptable estimation of ADs, yielding the lowest RMSE values for the kidney and tumour, calculated as (7\u2009\u00b1\u20092)% and (14\u2009\u00b1\u20094)%, respectively. The ADs in STP dosimetry showed lower precision than in ATP dosimetry. For instance, the ADs precision in ATP and STP dosimetry for kidneys in term median[min, max] were 3[3, 3]% and 6[5, 6]%, respectively. Similar results were found for the tumours where the precision of the ADs in ATP and STP dosimetry were 4[4, 5]% and 9[8, 12] %, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>STP dosimetry exhibits acceptable accuracy, although it shows a decrease in precision compared to ATP fitting. Precision information is clinically relevant for developing the optimal strategies for simplified dosimetry protocols.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40658-025-00726-7","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T05:03:39Z","timestamp":1742965419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Accuracy and precision analyses of single-time-point dosimetry utilising physiologically-based pharmacokinetic modelling and non-linear mixed-effects modelling"],"prefix":"10.1186","volume":"12","author":[{"given":"Indra","family":"Budiansah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deni","family":"Hardiansyah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ade","family":"Riana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriyanto Ardjo","family":"Pawiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambros J.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Glatting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"726_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/J.Zemedi.2013.03.005","volume":"23","author":"G Glatting","year":"2013","unstructured":"Glatting G, Bardi\u00e8s M, Lassmann M. Treatment planning in molecular radiotherapy. Z Med Phys. 2013;23:262\u20139. https:\/\/doi.org\/10.1016\/J.Zemedi.2013.03.005.","journal-title":"Z Med Phys"},{"key":"726_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/S00259-015-3248-6","volume":"43","author":"D Hardiansyah","year":"2016","unstructured":"Hardiansyah D, Maass C, Attarwala A, M\u00fcller B, Kletting P, Mottaghy F, et al. The role of patient-based treatment planning in peptide receptor radionuclide therapy. Eur J Nuclear Med Mol Imaging. 2016;43:871\u201380. https:\/\/doi.org\/10.1007\/S00259-015-3248-6.","journal-title":"Eur J Nuclear Med Mol Imaging"},{"key":"726_CR3","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/S00259-010-1549-3","volume":"38","author":"M Lassmann","year":"2011","unstructured":"Lassmann M, Chiesa C, Flux G, Bardies M, Committee E. EANM dosimetry committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging. 2011;38:192\u2013200. https:\/\/doi.org\/10.1007\/S00259-010-1549-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"726_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/S40658-024-00658-8","volume":"11","author":"L Vergnaud","year":"2024","unstructured":"Vergnaud L, Dewaraja Y, Giraudet A-L, Badel J-N, Sarrut D. A review of 177Lu dosimetry workflows: how to reduce the imaging workloads? EJNMMI Phys. 2024;11:65. https:\/\/doi.org\/10.1186\/S40658-024-00658-8.","journal-title":"EJNMMI Phys"},{"key":"726_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/S40658-024-00665-9","author":"S Spink","year":"2024","unstructured":"Spink S, Gillett D, Heard S, Harper I, Casey R, Aloj L. Estimation of kidney doses from [177lu]Lu-DOTA-TATE PRRT using single time point post-treatment SPECT\/CT. Ejnmmi Phys. 2024. https:\/\/doi.org\/10.1186\/S40658-024-00665-9.","journal-title":"Ejnmmi Phys"},{"key":"726_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/S13550-023-01007-Z","author":"AB Peterson","year":"2023","unstructured":"Peterson AB, Mirandi DM, Dewaraja YK. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT In patients and clinically realistic simulations. EJNMMI Res. 2023. https:\/\/doi.org\/10.1186\/S13550-023-01007-Z.","journal-title":"EJNMMI Res"},{"key":"726_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/S40658-020-00311-0","author":"A Rinscheid","year":"2020","unstructured":"Rinscheid A, Kletting P, Eiber M, Beer A, Glatting G. Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry. EJNMMI Phys. 2020. https:\/\/doi.org\/10.1186\/S40658-020-00311-0.","journal-title":"EJNMMI Phys"},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"7804","DOI":"10.7150\/Thno.77279","volume":"12","author":"H Siebinga","year":"2022","unstructured":"Siebinga H, De Wit-Van-De-Veen B, Stokkel M, Huitema A, Hendrikx J. Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review. Theranostics. 2022;12:7804\u201320. https:\/\/doi.org\/10.7150\/Thno.77279.","journal-title":"Theranostics."},{"key":"726_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/Ijerph20043473","author":"D Deepika","year":"2023","unstructured":"Deepika D, Kumar V. The role of \u201cphysiologically based pharmacokinetic model (PBPK)\u201d new approach methodology (Nam). Pharmac Environ Chem Risk Assess. 2023. https:\/\/doi.org\/10.3390\/Ijerph20043473.","journal-title":"Pharmac Environ Chem Risk Assess"},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.zemedi.2022.06.004","volume":"33","author":"D Hardiansyah","year":"2023","unstructured":"Hardiansyah D, Riana A, Beer A, Glatting G. Single-time-point estimation of absorbed doses In PRRT Using A Non-linear mixed-effects model. Z Med Phys. 2023;33:70\u201381.\u00a0https:\/\/doi.org\/10.1016\/j.zemedi.2022.06.004","journal-title":"Z Med Phys"},{"key":"726_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40658-018-0232-9","author":"KP Willowson","year":"2018","unstructured":"Willowson KP, Eslick E, Ryu H, Poon A, Bernard EJ, Bailey DL. Feasibility and accuracy of single time point imaging for renal dosimetry following 177Lu-DOTATATE (\u2018lutate\u2019) therapy. EJNMMI Phys. 2018. https:\/\/doi.org\/10.1186\/s40658-018-0232-9.","journal-title":"EJNMMI Phys"},{"key":"726_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/S00259-021-05538-2","volume":"49","author":"S Peters","year":"2022","unstructured":"Peters S, Hofferber R, Priv\u00e9 B, De Bakker M, Gotthardt M, Janssen M, et al. [68Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [177Lu]Lu-PSMA-617 treatment. Eur J Nuclear Med Mol Imaging. 2022;49:1101\u201312. https:\/\/doi.org\/10.1007\/S00259-021-05538-2.","journal-title":"Eur J Nuclear Med Mol Imaging"},{"key":"726_CR13","doi-asserted-by":"publisher","first-page":"767","DOI":"10.2967\/Jnumed.122.264594","volume":"64","author":"J Brosch-Lenz","year":"2023","unstructured":"Brosch-Lenz J, Delker A, V\u00f6lter F, Unterrainer L, Kaiser L, Bartenstein P, et al. toward single-time-point image-based dosimetry of 177Lu-PSMA-617 therapy. J Nuclear Med. 2023;64:767\u201374. https:\/\/doi.org\/10.2967\/Jnumed.122.264594.","journal-title":"J Nuclear Med"},{"key":"726_CR14","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1007\/S00259-018-4136-7","volume":"45","author":"J Gear","year":"2018","unstructured":"Gear J, Cox M, Gustafsson J, Gleisner K, Murray I, Glatting G, et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nuclear Med Mol Imaging. 2018;45:2456\u201374. https:\/\/doi.org\/10.1007\/S00259-018-4136-7.","journal-title":"Eur J Nuclear Med Mol Imaging"},{"key":"726_CR15","doi-asserted-by":"publisher","first-page":"566","DOI":"10.2967\/Jnumed.123.266268","volume":"65","author":"D Hardiansyah","year":"2024","unstructured":"Hardiansyah D, Yousefzadeh-Nowshahr E, Kind F, Beer A, Ruf J, Glatting G, et al. Single-time-point renal dosimetry using nonlinear mixed-effects modeling and population-based model selection In [177Lu]Lu-PSMA-617 therapy. J Nucl Med. 2024;65:566\u201372. https:\/\/doi.org\/10.2967\/Jnumed.123.266268.","journal-title":"J Nucl Med"},{"key":"726_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/S13139-024-00851-8","volume":"58","author":"A Jundi","year":"2024","unstructured":"Jundi A, Naqiyyun M, Patrianesha B, Mu\u2019minah I, Riana A, Hardiansyah D. Uncertainty analysis of time-integrated activity coefficient in single-time-point dosimetry using Bayesian fitting method. Nuclear Med Mol Imaging. 2024;58:120\u20138. https:\/\/doi.org\/10.1007\/S13139-024-00851-8.","journal-title":"Nuclear Med Mol Imaging"},{"key":"726_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/S13550-023-00952-Z","author":"S Peters","year":"2023","unstructured":"Peters S, Mink M, Priv\u00e9 B, De-Bakker M, De Lange F, Muselaers C, et al. Optimization of the radiation dosimetry protocol in lutetium-177-psma therapy: toward clinical implementation. Ejnmmi Res. 2023. https:\/\/doi.org\/10.1186\/S13550-023-00952-Z.","journal-title":"Ejnmmi Res"},{"key":"726_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.2967\/Jnumed.117.203505","volume":"59","author":"N Begum","year":"2018","unstructured":"Begum N, Thieme A, Eberhardt N, Tauber R, D\u2019alessandria C, Beer A, et al. The effect of total tumor volume on the biologically effective dose to tumor and kidneys for 177Lu-labeled psma peptides. J Nuclear Med. 2018;59:929\u201333. https:\/\/doi.org\/10.2967\/Jnumed.117.203505.","journal-title":"J Nuclear Med"},{"key":"726_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2967\/Jnumed.115.164699","volume":"57","author":"P Kletting","year":"2016","unstructured":"Kletting P, Kull T, Maa C, Malik N, Luster M, Beer A, et al. Optimized peptide amount and activity for 90Y-labeled dotatate therapy. J Nuclear Med. 2016;57:503\u20138. https:\/\/doi.org\/10.2967\/Jnumed.115.164699.","journal-title":"J Nuclear Med"},{"key":"726_CR20","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3413\/Nukmed-0283","volume":"49","author":"L Geworski","year":"2010","unstructured":"Geworski L, Schaefer A, Knoop B, Pinkert J, Plotkin M, Kirsch C. Physical aspects of scintigraphy-based dosimetry for nuclear medicine therapy. Nuklearmedizin. 2010;49:85\u201395. https:\/\/doi.org\/10.3413\/Nukmed-0283.","journal-title":"Nuklearmedizin"},{"key":"726_CR21","first-page":"37s","volume":"40","author":"J Siegel","year":"1999","unstructured":"Siegel J, Thomas S, Stubbs J, Stabin M, Hays M, Koral K, et al. Mird pamphlet No. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40:37s\u201361s.","journal-title":"J Nucl Med"},{"key":"726_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/S40658-023-00530-1","volume":"10","author":"D Hardiansyah","year":"2023","unstructured":"Hardiansyah D, Riana A, Beer A, Glatting G. Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept. Ejnmmi Phys. 2023;10:12. https:\/\/doi.org\/10.1186\/S40658-023-00530-1.","journal-title":"Ejnmmi Phys"},{"key":"726_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/9781118784860","volume-title":"Introduction to population pharmacokinetic\/pharmacodynamic analysis with nonlinear mixed effects models","author":"J Owen","year":"2014","unstructured":"Owen J, Fiedler-Kelly J. Introduction to population pharmacokinetic\/pharmacodynamic analysis with nonlinear mixed effects models. Wiley; 2014."},{"key":"726_CR24","first-page":"233","volume-title":"Nonlinear mixed effects models: theory","author":"PI Bonate","year":"2011","unstructured":"Bonate PI. Nonlinear mixed effects models: theory. US: springer; 2011. p. 233\u2013301."},{"key":"726_CR25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/Psp4.12404","volume":"8","author":"R Bauer","year":"2019","unstructured":"Bauer R. Nonmem tutorial part I: description of commands and options, with simple examples of population analysis. Cpt Pharmacometr Syst Pharmacol. 2019;8:525\u201337. https:\/\/doi.org\/10.1002\/Psp4.12404.","journal-title":"Cpt Pharmacometr Syst Pharmacol"},{"key":"726_CR26","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1002\/Mp.13846","volume":"46","author":"A Rinscheid","year":"2019","unstructured":"Rinscheid A, Kletting P, Eiber M, Beer A, Glatting G. Technical note: optimal sampling schedules for kidney dosimetry based on the hybrid planar\/spect method in 177Lu-PSMA therapy. Med Phys. 2019;46:5861\u20136. https:\/\/doi.org\/10.1002\/Mp.13846.","journal-title":"Med Phys"},{"key":"726_CR27","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/Psp4.12422","volume":"8","author":"R Bauer","year":"2019","unstructured":"Bauer R. Nonmem tutorial part ii: estimation methods and advanced examples. Cpt Pharmacometr Syst Pharmacol. 2019;8:538\u201356. https:\/\/doi.org\/10.1002\/Psp4.12422.","journal-title":"Cpt Pharmacometr Syst Pharmacol"},{"key":"726_CR28","first-page":"85","volume":"27","author":"H Kimura","year":"2006","unstructured":"Kimura H, Takeuchi H, Koshimoto Y, Arishima H, Uematsu H, Kawamura Y, et al. Perfusion imaging of meningioma by using continuous arterial spin-labeling: comparison with dynamic susceptibility-weighted contrast-enhanced MR images and histopathologic features. Ajnr Am J Neuroradiol. 2006;27:85\u201393.","journal-title":"Ajnr Am J Neuroradiol"},{"key":"726_CR29","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4329\/Wjr.V2.I11.449","volume":"2","author":"A Guyennon","year":"2010","unstructured":"Guyennon A, Mihaila M, Palma J, Lombard-Bohas C, Chayvialle J, Pilleul F. Perfusion characterization of liver metastases from endocrine tumors: computed tomography perfusion. World J Radiol. 2010;2:449\u201354. https:\/\/doi.org\/10.4329\/Wjr.V2.I11.449.","journal-title":"World J Radiol"},{"key":"726_CR30","first-page":"1023","volume":"46","author":"M Stabin","year":"2005","unstructured":"Stabin M, Sparks R, Crowe E. Olinda\/Exm: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023\u20137.","journal-title":"J Nucl Med."},{"key":"726_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/00004032-200309000-00006","volume":"85","author":"S Mg","year":"2003","unstructured":"Mg S, Ja S. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294\u2013310. https:\/\/doi.org\/10.1097\/00004032-200309000-00006.","journal-title":"Health Phys"},{"key":"726_CR32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/J.Zemedi.2018.12.001","volume":"29","author":"A Rinscheid","year":"2019","unstructured":"Rinscheid A, Lee J, Kletting P, Beer A, Glatting G. A simulation-based method to determine optimal sampling schedules for dosimetry in radioligand therapy. Z Med Phys. 2019;29:314\u201325. https:\/\/doi.org\/10.1016\/J.Zemedi.2018.12.001.","journal-title":"Z Med Phys."},{"key":"726_CR33","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/S00259-006-0317-X","volume":"34","author":"P Antunes","year":"2007","unstructured":"Antunes P, Ginj M, Zhang H, Waser B, Baum R, Reubi J, et al. Are radiogallium-labelled dota-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982\u201393. https:\/\/doi.org\/10.1007\/S00259-006-0317-X.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"726_CR34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/Mp.14622","volume":"48","author":"D Hardiansyah","year":"2021","unstructured":"Hardiansyah D, Kletting P, Begum N, Eiber M, Beer A, Pawiro S, et al. Important pharmacokinetic parameters for individualization of 177Lu-PSMA therapy: a global sensitivity analysis for a physiologically-based pharmacokinetic model. Med Phys. 2021;48:556\u201368. https:\/\/doi.org\/10.1002\/Mp.14622.","journal-title":"Med Phys"},{"key":"726_CR35","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/Psp4.12914","volume":"12","author":"H Siebinga","year":"2023","unstructured":"Siebinga H, Priv\u00e9 B, Peters S, Nagarajah J, Dorlo T, Huitema A, et al. Population pharmacokinetic dosimetry model using imaging data to assess variability in pharmacokinetics of 177Lu-PSMA-617 in prostate cancer patients. Cpt Pharmacometr Syst Pharmacol. 2023;12:1060\u201371. https:\/\/doi.org\/10.1002\/Psp4.12914.","journal-title":"Cpt Pharmacometr Syst Pharmacol"},{"key":"726_CR36","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/S40658-021-00427-X","volume":"8","author":"D Hardiansyah","year":"2021","unstructured":"Hardiansyah D, Riana A, Kletting P, Zaid N, Eiber M, Pawiro S, et al. A population-based method to determine the time-integrated activity in molecular radiotherapy. EJNMMI Phys. 2021;8:82. https:\/\/doi.org\/10.1186\/S40658-021-00427-X.","journal-title":"EJNMMI Phys"},{"key":"726_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/S40658-023-00530-1","author":"D Hardiansyah","year":"2023","unstructured":"Hardiansyah D, Riana A, Beer A, Glatting G. Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept. Ejnmmi Phys. 2023. https:\/\/doi.org\/10.1186\/S40658-023-00530-1.","journal-title":"Ejnmmi Phys"},{"key":"726_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/Jnumed.117.193706","volume":"59","author":"H H\u00e4nscheid","year":"2018","unstructured":"H\u00e4nscheid H, Lapa C, Buck A, Lassmann M, Werner R. Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC By A single measurement after 4 days. J Nucl Med. 2018;59:75\u201381. https:\/\/doi.org\/10.2967\/Jnumed.117.193706.","journal-title":"J Nucl Med"},{"key":"726_CR39","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1002\/Mp.12886","volume":"45","author":"M Madsen","year":"2018","unstructured":"Madsen M, Menda Y, O\u2019dorisio T, O\u2019dorisio M. Technical note: single time point dose estimate for exponential clearance. Med Phys. 2018;45:2318\u201324. https:\/\/doi.org\/10.1002\/Mp.12886.","journal-title":"Med Phys"},{"key":"726_CR40","doi-asserted-by":"publisher","DOI":"10.2967\/Jnumed.120.254656","author":"X Hou","year":"2020","unstructured":"Hou X, Brosch J, Uribe C, Desy A, Boning G, Beauregard J-M, et al. Feasibility of single-time-point dosimetry for radiopharmaceutical therapies. J Nuclear Med. 2020. https:\/\/doi.org\/10.2967\/Jnumed.120.254656.","journal-title":"J Nuclear Med"},{"key":"726_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/935351","volume":"2013","author":"F Guerriero","year":"2013","unstructured":"Guerriero F, Me F, Botta F, Fioroni F, Grassi E, Versari A, et al. Kidney dosimetry In 177Lu And 90Y peptide receptor radionuclide therapy: influence of image timing, time-activity integration method and risk factors. Biomed Res Int. 2013;2013:1\u201312. https:\/\/doi.org\/10.1155\/2013\/935351.","journal-title":"Biomed Res Int"}],"container-title":["EJNMMI Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-025-00726-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40658-025-00726-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-025-00726-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T05:03:57Z","timestamp":1742965437000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmiphys.springeropen.com\/articles\/10.1186\/s40658-025-00726-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1186\/s40658-025-00726-7","relation":{},"ISSN":["2197-7364"],"issn-type":[{"value":"2197-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The institutional review board (or equivalent) approved the retrospective study, and the requirement for informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read the manuscript and consented to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}